Clinical Research merges with Atlas Clinical Research

Alliance Clinical Network has merged with Atlas Clinical Research, a strategic move aimed at enhancing clinical trial recruitment and execution across a broadened geographical scope. The merger combines nearly five decades of clinical research experience, incorporating a network expansion across key U.S. states including Arizona, California, Florida, Nevada, New York, Pennsylvania, and Texas. Financial details of the merger were not disclosed.

The combined entity will operate under the leadership of Anthony Milonas as CEO, with headquarters in Southlake, Texas. The merger leverages both companies' complementary site footprints and therapeutic expertise in areas such as central nervous system (CNS) disorders, dermatology, gastroenterology, internal medicine, metabolic diseases, pain management, vaccines, and women's health. This partnership is poised to enhance patient recruitment and trial execution, benefiting pharmaceutical sponsors and contract research organizations (CROs) with greater consistency, speed, and quality in trial outcomes.

Strategically, the merger aims to fortify the companies' capabilities in research and enhance patient access, thereby streamlining processes for pharmaceutical sponsors facing complex drug development landscapes. Both Alliance and Atlas have emphasized maintaining high standards in patient care and operational execution. Mark Scullion, CEO of Atlas, highlighted that the merger creates a robust national platform that will better support sponsors in meeting intricate regulatory demands without compromising the firms’ culture and responsiveness.

Within the competitive clinical research sector, this merger positions the new entity to deliver expanded therapeutic solutions while optimizing operational efficiency. The partnership harnesses the strengths of each company to offer a more comprehensive service that meets increased demand for diverse and tailored clinical trials.

The merger follows backing from Amulet Capital Partners and BPOC, two private equity firms with expertise in scaling healthcare services organizations. Their continued support underscores a commitment to leveraging the combined strengths of Alliance and Atlas in pursuit of advanced clinical research solutions. The next step involves the integrated company accelerating its operational outcomes, further fortifying its position within the U.S. clinical research landscape.